Predictive Oncology Secures $15,000,000 Equity Line
November 20 2019 - 8:30AM
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology”
or “the Company”), focused on applying artificial intelligence
(“AI”) to personalized medicine and drug discovery, today announced
that it entered into a $15 million common stock purchase and
registration rights agreement with Oasis Capital, LLC, a Puerto
Rico limited liability company (“Oasis Capital”), to purchase from
the Company up to Fifteen Million Dollars ($15,000,000.00) of the
Company’s Common Stock.
Under the purchase agreement, Predictive
Oncology has the right to sell up to $15 million of its stock to
Oasis Capital over a 36-month period, upon satisfaction of the
conditions in the purchase agreement including the effectiveness of
a resale registration statement which has occurred. Predictive
Oncology will control the timing and amount of any sales to Oasis
Capital, and Oasis Capital is obligated to make purchases in
accordance with the purchase agreement. The equity purchase
agreement allows the Company to fund its needs in a more expedient
and cost-effective manner. The equity line is designed to provide a
capital runway and to take advantage of the milestones to advance
CancerQuest 2020.
When asked for his comment, Dr. Carl Schwartz
said, “With this equity line established, the financial road ahead
for Predictive Oncology has truly begun to smooth out. This equity
line should eliminate the need to go to the capital markets for
operational financing for the foreseeable future.” For a complete
breakdown of terms of the agreement you can go to our
website: https://www.predictive-oncology.com/ and review the
Form 8-K filed on October 24, 2019. We have set up a phone
number for incoming calls with any questions, and that is listed
below. You can also email to Info@MoneyInfo-llc.com with any
questions and to be included in our email delivery distribution
list for any and all POAI news, events, and information.
The offer and sale of the securities by
Predictive Oncology in the above transaction have not been
registered under the Securities Act of 1933, as amended (the
"Securities Act"), and have not been registered or qualified under
any state securities laws, and therefore may not be offered or sold
in the United States absent registration under the Securities Act
or an applicable exemption from such registration requirements, and
registration or qualification and under applicable state securities
or “Blue Sky” laws or an applicable exemption from such
registration or qualification requirements. Predictive Oncology
filed a registration statement with the SEC to register the resale
by Oasis Capital of the shares of common stock to be purchased by
Oasis Capital under the purchase agreement, and that registration
statement has been declared effective.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy the securities, nor
shall there be any sale of the securities in any state in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of such
state.
About Predictive Oncology
Inc.
Predictive Oncology (Nasdaq: POAI) operates
through five segments (Domestic, International, Clinical, CRO and
DCHIP), which contain four subsidiaries; Helomics, TumorGenesis,
Skyline Medical and Skyline Europe. Helomics applies artificial
intelligence to its rich data gathered from patient tumors to both
personalize cancer therapies for patients and drive the development
of new targeted therapies in collaborations with pharmaceutical
companies. Helomics’ CLIA-certified lab provides clinical testing
that assists oncologists in individualizing patient treatment
decisions, by providing an evidence-based roadmap for therapy. In
addition to its proprietary precision oncology platform, Helomics
offers boutique CRO services that leverage its TruTumor™,
patient-derived tumor models coupled to a wide range of multi-omics
assays (genomics, proteomics and biochemical), and an AI-powered
proprietary bioinformatics platform (D- CHIP) to provide a tailored
solution to its clients’ specific needs. Predictive Oncology’s
TumorGenesis subsidiary is developing a new rapid approach to
growing tumors in the laboratory, which essentially “fools” cancer
cells into thinking they are still growing inside a patient. Its
proprietary Oncology Discovery Technology Platform kits will assist
researchers and clinicians to identify which cancer cells bind to
specific biomarkers. Once the biomarkers are identified they can be
used in TumorGenesis’ Oncology Capture Technology Platforms which
isolate and help categorize an individual patient’s heterogeneous
tumor samples to enable the development of patient specific
treatment options. Helomics and TumorGenesis are focused on ovarian
cancer. Predictive Oncology’s Skyline Medical division markets its
patented and FDA cleared STREAMWAY System, which automates the
collection, measurement and disposal of waste fluid, including
blood, irrigation fluid and others, within a medical facility,
through both domestic and international divisions. The company has
achieved sales in five of the seven continents through both direct
sales and distributor partners. For more information, please visit
www.predictive-oncology.com.
Forward-looking Statements
Certain of the matters discussed in the press
release contain forward-looking statements that involve material
risks to and uncertainties in the Company’s business that may cause
actual results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include
(i) risks related to the recent merger with Helomics, including the
fact that the combined company will not be able to continue
operating without additional financing; possible failure to realize
anticipated benefits of the merger; costs associated with the
merger may be higher than expected; the merger may result in
disruption of the Company’s and Helomics’ existing businesses,
distraction of management and diversion of resources; and the
market price of the Company’s common stock may decline as a result
of the merger; (ii) risks related to our partnerships with
other companies, including the need to negotiate the definitive
agreements; possible failure to realize anticipated benefits of
these partnerships; and costs of providing funding to our partner
companies, which may never be repaid or provide anticipated
returns; and (iii) other risks and uncertainties relating to the
Company that include, among other things, current negative
operating cash flows and a need for additional funding to finance
our operating plan; the terms of any further financing, which may
be highly dilutive and may include onerous terms; unexpected costs
and operating deficits, and lower than expected sales and revenues;
sales cycles that can be longer than expected, resulting in delays
in projected sales or failure to make such sales; uncertain
willingness and ability of customers to adopt new technologies and
other factors that may affect further market acceptance, if our
product is not accepted by our potential customers, it is unlikely
that we will ever become profitable; adverse economic conditions;
adverse results of any legal proceedings; the volatility of our
operating results and financial condition; inability to attract or
retain qualified senior management personnel, including sales and
marketing personnel; our ability to establish and maintain the
proprietary nature of our technology through the patent process, as
well as our ability to possibly license from others patents and
patent applications necessary to develop products; Predictive’s
ability to implement its long range business plan for various
applications of its technology; Predictive’s ability to enter into
agreements with any necessary marketing and/or distribution
partners and with any strategic or joint venture partners; the
impact of competition, the obtaining and maintenance of any
necessary regulatory clearances applicable to applications of
Predictive’s technology; and management of growth and other risks
and uncertainties that may be detailed from time to time in the
Company’s reports filed with the SEC, which are available for
review at www.sec.gov. This is not a solicitation to buy or sell
securities and does not purport to be an analysis of Predictive’s
financial position. See Predictive’s most recent Annual Report on
Form 10-K, and subsequent reports and other filings at
www.sec.gov.
Contact:Charles
Moskowitzinfo@MoneyInfo-LLC.com339-201-7457
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024